Rezolute, Inc.

NEWS

Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and Much More

Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.

March 25, 2022

10 min read

Mark Terry

Business

BioSpace Movers & Shakers, March 12

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

March 11, 2021

7 min read

Alex Keown

JOBS

IN THE PRESS

Business

Rezolute Reports First Quarter Fiscal 2024 Results

November 13, 2023

6 min read

Policy

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

October 17, 2023

6 min read

Biotech Bay

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

October 11, 2023

6 min read

Business

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

September 14, 2023

6 min read

Drug Development

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

June 27, 2023

7 min read

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

June 1, 2023

1 min read

Drug Development

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

May 11, 2023

5 min read

Biotech Bay

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

March 23, 2023

7 min read

Drug Development

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

March 8, 2023

5 min read

Business

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

February 10, 2023

5 min read